Global Opioid Induced Constipation (OIC) Drugs Market Growth 2025-2031
Description
The global Opioid Induced Constipation (OIC) Drugs market size is predicted to grow from US$ 2827 million in 2025 to US$ 3740 million in 2031; it is expected to grow at a CAGR of 4.8% from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
LP Information, Inc. (LPI) ' newest research report, the “Opioid Induced Constipation (OIC) Drugs Industry Forecast” looks at past sales and reviews total world Opioid Induced Constipation (OIC) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Opioid Induced Constipation (OIC) Drugs sales for 2025 through 2031. With Opioid Induced Constipation (OIC) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioid Induced Constipation (OIC) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Opioid Induced Constipation (OIC) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid Induced Constipation (OIC) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioid Induced Constipation (OIC) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid Induced Constipation (OIC) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid Induced Constipation (OIC) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid Induced Constipation (OIC) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Opioid Induced Constipation (OIC) Drugs market?
What factors are driving Opioid Induced Constipation (OIC) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Opioid Induced Constipation (OIC) Drugs market opportunities vary by end market size?
How does Opioid Induced Constipation (OIC) Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
LP Information, Inc. (LPI) ' newest research report, the “Opioid Induced Constipation (OIC) Drugs Industry Forecast” looks at past sales and reviews total world Opioid Induced Constipation (OIC) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Opioid Induced Constipation (OIC) Drugs sales for 2025 through 2031. With Opioid Induced Constipation (OIC) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Opioid Induced Constipation (OIC) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Opioid Induced Constipation (OIC) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Opioid Induced Constipation (OIC) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Opioid Induced Constipation (OIC) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Opioid Induced Constipation (OIC) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Opioid Induced Constipation (OIC) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid Induced Constipation (OIC) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Opioid Induced Constipation (OIC) Drugs market?
What factors are driving Opioid Induced Constipation (OIC) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Opioid Induced Constipation (OIC) Drugs market opportunities vary by end market size?
How does Opioid Induced Constipation (OIC) Drugs break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
131 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Opioid Induced Constipation (OIC) Drugs by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Opioid Induced Constipation (OIC) Drugs by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
